Pharming Group Nv (PHAR) has released an update.
Pharming Group N.V. has been recognized as an Industry Innovator at the National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards for its work on Joenja®, the first FDA-approved treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency. This milestone honors the company’s successful commercialization of the drug, which is now providing treatment options for adults and children over 12 with APDS, and highlights the company’s commitment to addressing rare diseases with limited therapeutic options.
For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.
